Leveragen

Leveragen is a genetic engineering company focused on developing next-generation genetic models for antibody discovery. By leveraging CRISPR gene editing, synthetic biology, and chromosome engineering technologies, Leveragen is building a series of genetic platforms to facilitate the discovery of diverse biological models for the development of new diagnostics and therapies. Leveragen's flagship platform, the Singularity Sapiens Mouse, specializes in producing human heavy-chain antibodies from the endogenous mouse locus, marking a significant breakthrough in the field of single-domain antibody development. This innovative technology ensures the faithful expression of human immunoglobulin genes while eliminating conventional antibodies, promoting optimal B-cell development and robust immune responses from diverse human antibody libraries. As a result, the fully human single-domain antibodies derived from this platform exhibit superior affinity, stability, solubility, and modularity. Furthermore, the unique single-sequence nature of single-domain antibodies supports next-generation sequencing-driven workflows, enhancing the speed, scope, and efficiency of antibody discovery and accelerating the creation of more effective targeted therapies.